Objectives: To systematically review the incidence and factors associated with recurrences or new tumors after apparent complete resection of pheochromocytoma or thoraco-abdomino-pelvic paraganglioma. Design: A systematic review and meta-analysis of published literature was performed. Methods: Pubmed and Embase from 1980 to 2012 were searched for studies published in English on patients with non-metastatic pheochromocytoma or thoraco-abdomino-pelvic paraganglioma, complete tumor resection, postoperative follow-up exceeding 1 month, and recurrence or new tumor documented by pathology, hormonal dosages, or imaging tests. Incidence rates of new events after curative surgery were calculated for each study that had sufficient information and pooled using random-effect meta-analysis. Results: In total, 38 studies were selected from 3518 references, of which 36 reported retrospective cohorts from the USA, Europe, and Asia. Patient follow-up was neither standardized nor exhaustive in the included studies. A clear description of patient retrieval methods was available for nine studies and the follow-up protocol and patient flow for four studies. Only two studies used multivariable methods to assess potential predictors of postoperative events. The overall rate of recurrent disease from 34 studies was 0.98 events/100 person-years (95% confidence interval 0.71, 1.25). Syndromic diseases and paragangliomas were consistently associated with a higher risk of a new event in individual studies and in meta-regression analysis. Conclusions: The risk of recurrent disease after complete resection of pheochromocytoma may be lower than that previously estimated, corresponding to five events for 100 patients followed up for 5 years after complete resection. Risk stratification is required to tailor the follow-up protocol after complete resection of a pheochromocytoma or paraganglioma. Large multicenter studies are needed to this end.
Introduction
Pheochromocytomas and paragangliomas (PH/PG) are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla or sympathetic and parasympathetic paraganglia respectively. Following resection of the primary tumor, most patients are free of tumor with no clinical, biochemical, or imaging evidence of persistent disease. However, tumor-free patients are at a risk of long-term recurrence, defined as the reappearance of disease after complete surgical eradication of the tumor (1) . Recurrences may arise at the operated site or may be metastatic, developing in non-chromaffin organs, mainly the lymph nodes, bones, lungs, and liver (2, 3) . Patients with inherited tumors may also develop new PH/PGs in the contralateral adrenal gland or in other paraganglia (3, 4) . At least 15% of patients undergoing surgery for PH/PG develop new tumors or recurrences, most of which are metastatic (4) . Consequently, long-term follow-up is recommended for patients who have undergone surgery for PH/PG (5) .
Although there are reports of the prognostic value of various clinical, genetic, and pathological features, there are no robust prognostic indices of recurrence other than the higher probability of new events in patients with inherited tumors and possibly in patients with extra-adrenal or large tumors (4, 5) . The total duration of follow-up that is required remains unclear, as new events may occur decades after initial surgery. The optimal combination and sequence of biochemical and imaging tests to detect and monitor recurrences are poorly defined. There have been no comprehensive systematic reviews assessing the incidence of recurrences or new tumors following surgery for PH/PG.
Our primary objective is to systematically review the incidence of local or metastatic recurrences or new tumors in patients who have undergone apparently complete resection of a non-metastatic PH/PG. A secondary objective is to assess the factors associated with recurrences (local or metastatic) or new tumors.
Methods

Eligibility criteria
We searched randomized or non-randomized controlled trials, prospective or retrospective cohort studies, and case-control studies published in English in 1980 or later (computed tomography and metanephrine determinations were not universally available before 1980). Studies were eligible if (i) they enrolled at least 20 patients with PH/ PG; (ii) patients had reportedly undergone complete tumor resection; (iii) postoperative follow-up exceeded 1 month (arbitrarily); and (iv) the number of patients with recurrence or new tumor could be identified.
Information sources and search
We searched Medline and Embase databases from 01/01/1980 to 10/19/2012. We developed a specific search strategy for each database and is presented in Supplementary Methods (see section on supplementary data given at the end of this article).
Study selection
Two physicians, experts in endocrine hypertension (L A and C L), independently made a first selection using the titles, abstracts, and keywords to exclude studies that clearly did not fulfill the inclusion criteria. They independently read the full text of the remaining papers to identify eligible articles. At each stage, disagreements between readers were resolved by discussion or, if necessary, by a third reader (P F P or J L). Journals and authors were not blinded during study selection. In cases of overlapping publications by a given team, only the most comprehensive or most recent was included.
The studies were then further subdivided into two categories: (i) studies on head and neck paraganglioma only and (ii) studies on pheochromocytoma and thoracoabdomino-pelvic paraganglioma. This review reports only the results of the latter category of studies.
Data collection
A standardized form was tested on ten articles and two senior experts (P F P and J L) to homogenize further data collection. The form was then used by two abstractors (L A and C L) to extract methodological and clinical data from all included studies. Records were reviewed by a third reader and issues were resolved by discussion. Journals, titles, and authors were not blinded during data abstraction.
The following data were collected from each study: first author and publication year; study design and settings; number of centers, total number and number of operated patients with complete tumor resection; risk of bias; percentage of female patients, mean age, percentage of hypertensive patients, percentage of patients with pheochromocytoma, location of paragangliomas, mean tumor size, percentage of secreting tumors, and percentage of genetic or syndromic diseases; number of patients with follow-up and duration of follow-up; incidence of recurrence, timing of recurrence, and attributable deaths.
Quality assessment
No agreed criteria exist for assessing the risk of bias of prognostic studies. We used several resources to compile a list of criteria to assess the risk of bias regarding study participants, prognostic factors, outcome, follow-up, and reporting. Further details are provided in the Supplementary Methods.
Summary measures
Incidence rates of recurrence or new tumor over the entire duration of the follow-up were calculated by dividing the number of events by the number of person-years of follow-up, and then standardized to the number of events/100 person-years. The mean duration of follow-up was multiplied by the number of patients when the number of person-years of follow-up was not reported. When the mean duration of follow-up was not reported, it was approximated by a formula using the median and range when available (6, 7) , or by the median in other cases. We assumed the Poisson distribution to estimate 95% confidence intervals for the rate of events presented in forest plots. Meta-analysis was performed on rates and their confidence interval limits. Heterogeneity was Figure 1 Study flow diagram. fU, follow-up; Hn, head and neck; PH/PG, pheochromocytomas and paragangliomas; PG, paragangliomas. assessed using Cochran statistic and the I² inconsistency coefficient. An I² value greater than 50% was considered to be indicative of substantial heterogeneity. Study results were pooled using random-effect meta-analysis. We used Stata SE/MP version 9.2 (StataCorp) for the analyses.
Additional analyses
We performed sensitivity analyses based on the availability of the mean duration of follow-up (allowing to compute the exact incidence rate) and by risk of bias. A funnel plot of the event rate according to the number of person-years of follow-up (a substitute for the precision of estimates) was used to assess publication bias.
Meta-regression analysis was used to assess the impact of the following variables on the logarithm of incidence rates: operation year of the first patient, specialty of the author team (surgery vs others), percentage of females, mean age, percentage of familial diseases (genetic or syndromic), percentage of pheochromocytomas, mean size of the tumor, and mean duration of follow-up.
Results
Study selection
The details of the selection process and reasons for exclusions are depicted in the flow chart (Fig. 1) . Bibliographic searches yielded 3518 references, among which 42 on pheochromocytoma and thoraco-abdominopelvic paraganglioma were finally selected, reporting 38 different cohorts.
Study characteristics
The characteristics of the included studies are reported in Table 1 .
All studies were on retrospective cohorts except one on a prospective cohort (44) and one that was a randomized controlled trial (45) . Of the 38 studies, 20 were performed in Europe, nine in North America, six in Asia, two in South America, and one in the Middle East. The inception year ranged from 1950 to 2000 (median 1985). Studies involved 1-21 centers; 20 studies were performed by surgical teams, ten by medical teams, seven by both, and one by laboratory physicians. 
Risk of bias within studies
Detailed risks of bias of the included studies are reported in the Supplementary Table 1 . Only nine studies explained how they ensured the completeness of patient retrieval (for instance, through a prospectively maintained research database or administrative databases with diagnostic coding). Only four studies provide a clear and specific description of patient flow (inclusion, operation, cure, and follow-up). Fourteen studies looked for prognostic factors, but only two performed multivariate analyses.
Patient and disease characteristics
Patient and disease characteristics are reported in Table 2 . The percentage of females was reported in 35 studies and was between 36 and 67% (median 54%). The mean or median age was reported in 35 studies and was between 27 and 53 years (median 42 years). The percentage of hypertensive patients was reported in 25 studies and was between 3 and 98% (median 66%). The percentage of syndromic or genetic disease was reported in 32 studies. Of the 32 studies, four involved only patients with a syndromic disease (VHL, NF1, or MEN2). In the 
Results of individual studies
Raw results of individual studies are reported in Table 3 . The number of patients followed up after complete surgical resection was between 22 and 242 (median 52). The mean or median duration of follow-up was available for 34 studies and was between 14 and 180 months (median 84 months). The percentage of recurrent disease over the entire follow-up was between 1 and 34% (median 6%). Eleven studies (51 events) provided individual data on the time from surgery to recurrent disease, with an overall median time to event of 60 months (range 3-204), and two studies (26 events) provided summary results with median times to event of 17 and 29 months Events/100 person-years (95% confidence interval) Figure 2 forest plot of new event rates.
(range . Two studies (7 events) did not provide any information on the time to the recurrent event.
Candidate prognostic markers assessed by one or more individual studies are reported in Supplementary Table 2 . Paragangliomas (hazard ratios 11 and 8.8 compared with pheochromocytomas) and syndromic diseases (hazard ratios 3.4 and 14 compared with sporadic diseases) were independently associated with an increased risk of a new event after curative surgery in two studies (9, 37) and larger tumor size in one study (hazard ratio 1.2 for each supplementary centimeter in tumor diameter) (9) . Paragangliomas were also associated with new events by univariate analyses in one additional study but not in two others. Larger tumor size was also associated with an increased risk of a new event by univariate analysis in an additional study but not in three others.
Synthesis of results
The new event rate estimates of 34 studies with follow-up duration data showed significant heterogeneity (I² 51%, P < 0.001; Fig. 2 ). Random-effect meta-analysis produced an overall new event rate estimate of 0.95 events/100 person-years (95% confidence interval (CI) 0.68, 1.21). Assuming a steady incidence over time, this converts into a 5-year cumulative incidence of 4.7% (95% CI: 3.4, 6.1; Fig. 2 ), distrib uted as follows: new tumors 22%, local recurrences 23%, and metastatic recurrences 55%.
The pooled estimate of event rate was as follows:
-0.98 events/100 person-years (95% CI: 0.68, 1.29) across studies allowing the calculation of the exact number of person-years of follow-up; -1.18 events/100 person-years (95% CI: 0.71, 1.66) across studies with the lowest risk of bias (at most five risks regarding participants, outcome, follow-up, or results); -1.11 events/100 person-years (95% CI: 0.56, 1.66) across studies fulfilling both conditions.
Risk of bias across studies
The funnel plot of incidence rate against person-years of follow-up shows that the estimated incidence rate of several studies deviates from the overall estimate ( Supplementary Fig. 1 ).
Meta-regression analysis
The percentage of genetic or syndromic disease was associated with the rate of new events ( Fig. 3 and Supplementary Fig. 2 ). The pooled event rate estimate was 0.79 events/100 person-years (95% CI: 0.53, 1.04) for studies with less than 60% genetic or syndromic diseases (I² 40%, P = 0.03) and 2.24 events/100 person-years (95% CI: 1.62, 2.87) for studies with 60% or higher genetic or syndromic diseases (I² 0%, P = 0.51). A younger mean age was also associated with a higher rate of new events; however, this association disappeared in a multivariate model including both the mean age and the percentage of genetic or syndromic disease. Other variables were not associated with the new event rate in meta-regression analyses (Supplementary Table 3 ).
Discussion
Summary
Our review suggests that the risk of recurrent disease following complete resection of a pheochromocytoma or a thoraco-abdomino-pelvic paraganglioma is lower than that previously estimated. However, the risk remains nonnegligible, approximately 5% per 5 years of follow-up, and late events are possible, up to 15 years after surgery in the included studies. Paragangliomas and familial disease are the two main independent risk factors of recurrent disease identified by several studies and by meta-regression analyses across studies. The association between the size of the primary tumor and the risk of recurrence after complete removal was weaker.
Limitations of evidence
The reporting of methodological details and clinical results of the included studies was very heterogeneous.
Most studies were retrospective, and patient follow-up was neither standardized nor exhaustive. The time pattern of recurrence risk (early vs late) was not assessed, and data were scarce after the first 10 years of follow-up, precluding any firm conclusion beyond this horizon, although recurrent disease is clearly still possible. Risk factors were not consistently assessed across studies and only a few had available genetic data. It is now estimated that around 40% of all PH/PG arise in patients carrying a germline mutation in one of the 13 susceptibility genes identified so far (50). Individual patient data were not available, and meta-regression analyses were limited by an incomplete description of patients and disease in individual studies.
Implications
The overall low frequency of recurrent disease after complete resection of a PH/PG calls into question the need for lifelong follow-up after surgery for all patients. This contradicts the estimates from a previous review of published studies that did not take the varying mean duration of follow-up into account (3). Nonetheless, recurrent disease remains possible even after a long and uneventful follow-up and appears to be more frequent in patients with paragangliomas or familial disease than patients with sporadic pheochromocytoma. The follow-up protocol may need to be tailored according to these and other patient and disease characteristics. In particular, several studies that did not meet our inclusion criteria consistently show that germline mutations, even in apparently sporadic cases, are also associated with more aggressive disease and would benefit from intensive follow-up (5). The results of this systematic review do not allow any conclusion concerning the necessary length and frequency of follow-up after surgery and further research is warranted. Given the rarity of the disease and the number of candidate risk factors, multicenter studies with consistent documentation of the phenotype and genotype of included patients are needed to overcome the limitations of available evidence and reach the power necessary for multivariate prognostic analyses.
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